Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05498714
Other study ID # WDRY2022-K082
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 18, 2022
Est. completion date June 30, 2023

Study information

Verified date August 2022
Source Renmin Hospital of Wuhan University
Contact Mingkai Chen, Ph.D & M.D
Phone 13720330580
Email chenmingkai@whu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to observe the difference in bowel preparation quality between compound sodium picosulfate#CSP combined with lactulose and polyethylene glycol electrolyte#PEG combined with lactulose in high-risk population.


Description:

The quality of bowel preparation is crucial for colonoscopy. Some high-risk factors for inadequate bowel preparation have been identified , including age >70, previous colon surgery, constipation, diabetes, Parkinson's disease, history of stroke or spinal cord injury, prior history of inadequate bowel preparation, body mass index (BMI) >25, use of tricyclic antidepressant or narcotics. Patients were considered as high risk if they have any of the above factors.This is a single-center ,endoscopist-blinded study to compare the efficacy of CSP combined with lactulose and PEG combined with lactulose in bowel preparation. In colonoscopy procedures, endoscopists who were blinded to the intervention evaluated the overall quality of colonoscopy cleaning according to the Boston Bowel Preparation Scale. Patients' tolerance, defecation, adverse events and adenoma detection rate (ADR) were also evaluated.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date June 30, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:Adults undergoing colonoscopy who have at least one risk factor: age>70, previous colon surgery, constipation, diabetes, Parkinson's disease, history of stroke or spinal cord injury, prior history of inadequate bowel preparation, body mass index (BMI) >25, use of tricyclic antidepressant or narcotics. Exclusion Criteria: 1. presence of any contraindications for colonoscopy (gastrointestinal obstruction or perforation,severe acute inflammatory bowel disease,toxic megacolon,severe heart failure,unable to swallow,severe heart failure,etc); 2. Patients with galactosemia; 3. hypersensitivity to any of the ingredients; 4. Pregnancy or lactation; 5. Use of lactulose,prokinetic agents or purgatives within 7 days; 6. Unwilling to sign informed consent.

Study Design


Related Conditions & MeSH terms

  • Bowel Preparation Before Colonoscopy

Intervention

Drug:
PEG+lactulose
On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 1 L of PEG at 8:00 PM. On the day of the procedure, patients took 50 mL lactulose solution and the remaining 2 L of PEG 4-6 hours before colonoscopy.
CSP+lactulose
On the day before colonoscopy , Patients took 50mL lactulose solution at 7:00 PM. And then Patients began to drink 150 mL of CSP at 8:00 PM ,followed by 2000ml of clarified liquid. On the day of the procedure, 4-6 hours before colonoscopy, patients took 50 mL lactulose solution and the remaining 150mL of CSP ,then followed by 750ml of clarified liquid .

Locations

Country Name City State
China Renmin Hospital of Wuhan University Wuhan Hubei

Sponsors (1)

Lead Sponsor Collaborator
Renmin Hospital of Wuhan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Boston Bowel Preparation Scale Cleanliness of the colon during colonoscopy will be evaluated by the Boston Bowel Preparation Scale which is a 4-point scoring system applied to each of 3 broad regions of the colon: the right side, the transverse section, and the left side. The total BBPS score ranged from 0 to 9. If total BostonBowel Preparation Score =6 with each segmental BBPS=2, we regard it as adequate bowel preparation. during colonoscopy
Secondary Adenoma Detection Rate Diagnosis was confirmed by histologic examination 2 days
Secondary Polyp Detection Rate Diagnosis was confirmed by histologic examination 2 days
Secondary Rate of adverse events adverse events, such as vomiting, nausea, headache, abdominal distention, abdominal pain. 2 days
Secondary Cecal intubation rate Colonoscopy reaches cecal region. during colonoscopy
Secondary Cecal intubation time Colonoscopy reaches cecal region. during colonoscopy
Secondary Withdrawal time The time from the cecum to the anus, but excluded time for biopsy performance or removal of polyps. during colonoscopy
Secondary defecation frequency Frequency of bowel movement. 2 days
Secondary patient satisfaction Assessment Patients' satisfaction score for bowel preparation (3 points: completely tolerable and very satisfied; 2 points: nausea and other discomfort, but still tolerable and satisfactory; 1: unable to tolerate, not satisfied);
And whether the patient is willing to use the bowel cleansing program for colonoscopy;
2 days
See also
  Status Clinical Trial Phase
Completed NCT01984008 - A Study of the Efficacy and Safety of Bowklean and Klean-Prep With Dulcolax for the Bowel Preparation Prior Colonoscopy Phase 3
Completed NCT01745835 - Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation Phase 3
Completed NCT02910440 - A Safety and Efficacy Study of DCL-101 Compared to GoLYTELY Phase 2
Recruiting NCT05054036 - MoviPrep® Versus GoLYTELY® Bowel Preparation in Hospitalized Patients Undergoing Colonoscopy Phase 4
Completed NCT04582942 - Improved Bowel Preparation Method for Colonoscopy Based on Different Risk Stratification N/A
Recruiting NCT03106922 - A Trial to Evaluate the Efficacy and Safety of PMF104 Compared to a Conventional PEG-electrolyte Solution in Children Phase 3